206 related articles for article (PubMed ID: 23867129)
1. Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial.
Nijkamp MM; Span PN; Terhaard CH; Doornaert PA; Langendijk JA; van den Ende PL; de Jong M; van der Kogel AJ; Bussink J; Kaanders JH
Eur J Cancer; 2013 Oct; 49(15):3202-9. PubMed ID: 23867129
[TBL] [Abstract][Full Text] [Related]
2. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.
Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Marres HA; de Bree R; van der Kogel AJ; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
J Clin Oncol; 2012 May; 30(15):1777-83. PubMed ID: 22508814
[TBL] [Abstract][Full Text] [Related]
3. Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial.
Rademakers SE; Hoogsteen IJ; Rijken PF; Oosterwijk E; Terhaard CH; Doornaert PA; Langendijk JA; van den Ende P; Takes R; De Bree R; van der Kogel AJ; Bussink J; Kaanders JH
Radiother Oncol; 2013 Sep; 108(3):517-22. PubMed ID: 23719582
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck.
Eriksen JG; Steiniche T; Askaa J; Alsner J; Overgaard J
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):561-6. PubMed ID: 14751528
[TBL] [Abstract][Full Text] [Related]
5. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.
Kaanders JH; Wijffels KI; Marres HA; Ljungkvist AS; Pop LA; van den Hoogen FJ; de Wilde PC; Bussink J; Raleigh JA; van der Kogel AJ
Cancer Res; 2002 Dec; 62(23):7066-74. PubMed ID: 12460928
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: results of the accelerated radiotherapy with carbogen breathing and nicotinamide phase III randomized trial.
Rademakers SE; Hoogsteen IJ; Rijken PF; Terhaard CH; Doornaert PA; Langendijk JA; van den Ende P; van der Kogel AJ; Bussink J; Kaanders JH
Head Neck; 2015 Feb; 37(2):171-6. PubMed ID: 24347430
[TBL] [Abstract][Full Text] [Related]
7. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
Hoogsteen IJ; Pop LA; Marres HA; Merkx MA; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):83-9. PubMed ID: 16213107
[TBL] [Abstract][Full Text] [Related]
8. Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial.
Janssens GO; van Bockel LW; Doornaert PA; Bijl HP; van den Ende P; de Jong MA; van den Broek GB; Verbist BM; Terhaard CH; Span PN; Kaanders JH
Eur J Cancer; 2014 Apr; 50(6):1112-9. PubMed ID: 24424106
[TBL] [Abstract][Full Text] [Related]
9. The expression of EGFR, cerbB2, p16, and p53 and their relationship with conventional parameters in squamous cell carcinoma of the larynx.
Şimşek H; Han Ü; Önal B; Şimişek G
Turk J Med Sci; 2014; 44(3):411-6. PubMed ID: 25558642
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
Jonathan RA; Wijffels KI; Peeters W; de Wilde PC; Marres HA; Merkx MA; Oosterwijk E; van der Kogel AJ; Kaanders JH
Radiother Oncol; 2006 Jun; 79(3):288-97. PubMed ID: 16730088
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.
Bentzen SM; Atasoy BM; Daley FM; Dische S; Richman PI; Saunders MI; Trott KR; Wilson GD
J Clin Oncol; 2005 Aug; 23(24):5560-7. PubMed ID: 16110017
[TBL] [Abstract][Full Text] [Related]
12. Correlation and colocalization of HIF-1α and pimonidazole staining for hypoxia in laryngeal squamous cell carcinomas: A digital, single-cell-based analysis.
Swartz JE; Smits HJG; Philippens MEP; de Bree R; H A M Kaanders J; Willems SM
Oral Oncol; 2022 May; 128():105862. PubMed ID: 35447566
[TBL] [Abstract][Full Text] [Related]
13. Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma.
Pedicini P; Nappi A; Strigari L; Jereczek-Fossa BA; Alterio D; Cremonesi M; Botta F; Vischioni B; Caivano R; Fiorentino A; Improta G; Storto G; Benassi M; Orecchia R; Salvatore M
Radiat Oncol; 2012 Aug; 7():143. PubMed ID: 22920680
[TBL] [Abstract][Full Text] [Related]
14. The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma.
Eriksen JG; Steiniche T; Overgaard J;
Acta Oncol; 2005; 44(1):50-8. PubMed ID: 15848906
[TBL] [Abstract][Full Text] [Related]
15. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study.
Eriksen JG; Steiniche T; Overgaard J;
Radiother Oncol; 2005 Feb; 74(2):93-100. PubMed ID: 15816106
[TBL] [Abstract][Full Text] [Related]
16. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).
Bernier J; Denekamp J; Rojas A; Minatel E; Horiot J; Hamers H; Antognoni P; Dahl O; Richaud P; van Glabbeke M; Piérart M
Radiother Oncol; 2000 May; 55(2):111-9. PubMed ID: 10799722
[TBL] [Abstract][Full Text] [Related]
17. HIF-1α and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma.
Kwon OJ; Park JJ; Ko GH; Seo JH; Jeong BK; Kang KM; Woo SH; Kim JP; Hwa JS; Carey TE
Head Neck; 2015 Apr; 37(4):505-10. PubMed ID: 24677746
[TBL] [Abstract][Full Text] [Related]
18. Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.
Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Takes RP; de Bree R; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
Clin Cancer Res; 2014 Mar; 20(5):1345-54. PubMed ID: 24452791
[TBL] [Abstract][Full Text] [Related]
19. Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
Janssens GO; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Pop LA; Kaanders JH
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):532-8. PubMed ID: 21300447
[TBL] [Abstract][Full Text] [Related]
20. The EGFR-mTOR pathway and laryngeal cancer angiogenesis.
Lionello M; Lovato A; Staffieri A; Blandamura S; Turato C; Giacomelli L; Staffieri C; Marioni G
Eur Arch Otorhinolaryngol; 2014 Apr; 271(4):757-64. PubMed ID: 24065188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
